Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis
Antonio D’Alessio(Imperial College London), David J. Pinato(Imperial College London), Maria Isabel Fiel(Icahn School of Medicine at Mount Sinai), Ciro Celsa(Hammersmith Hospital), Daniel Shu(University of Maryland, Baltimore), Marina Baretti(Johns Hopkins University), Vincent Yip(Barts Health NHS Trust), Claudia Angela Maria Fulgenzi(Università Campus Bio-Medico), Robert Goldin(Imperial College London), Thomas U. Marron(Icahn School of Medicine at Mount Sinai), Yung‐Yeh Su(National Cheng Kung University Hospital), Alessio Cortellini(Hammersmith Hospital), Giulia Francesca Manfredi(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Chiun Hsu(National Taiwan University), Bernardo Stefanini(University of Bologna), Mark Yarchoan(Johns Hopkins University), Julia Blanter(Mount Sinai Hospital), Fionnuala Crowley(Mount Sinai Hospital), Robert Anders(Johns Hopkins University), Stephen C. Ward(Icahn School of Medicine at Mount Sinai), Madhava Pai(Imperial College London), Sarah Slater(Barts Health NHS Trust), Benjamin Adegbite(Mount Sinai Hospital)
Cited by 64
Related Papers
An inflammatory cytokine signature predicts COVID-19 severity and survival
|Nature Medicine|2020|2.7k
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial
|The Lancet Oncology|2013|728
2016 Comprehensive Update of the Banff Working Group on Liver Allograft Pathology: Introduction of Antibody-Mediated Rejection
|American Journal of Transplantation|2016|628